Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, opioid
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why it matters: Millions of Americans with acute and chronic pain are prescribed opioids,
FDA approves opioid-free pain medication with 'no sign of addiction'
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. Doctors share what patients should know about the drug.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
22h
Fighting addiction means taking a hard look at opioid prescribing
NSDUH only queried opioid misusers about opioid use disorder symptoms. After they changed the protocol and asked all ...
News Medical on MSN
2d
Pain coping skills training reduces pain and improves quality of life for dialysis patients
People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...
1d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Pauses tariffs on Mexico
'USAID to be shut down'
Wins album of the year
North Korea slams Rubio
Protest in Los Angeles
Wrongful arrest settlement
Staff must reveal probe role
US stock market falls
Workers put on leave
Plans to cut South Africa aid
Winter storm warnings
Venezuelan protections end
Martinez refinery fire
Sweden rules out sabotage
On trial over World Cup kiss
Set up joint company
Elliott wins Cook Out Clash
Philly plane crash probe
Ex-MLB commissioner dies
RU energy facilities attacked
Syria car bomb explosion
Teething sticks recalled
Grammy Awards winners
Wins 27th PGA Tour title
Agent for ‘deep research’
Japan's navigation satellite
Explosions in West Bank
Kelce fined for taunting
Phil predicts more winter
DOGE gains access to data
Feedback